Core Insights - Compass Therapeutics, Inc. has initiated an Investigator Sponsored Trial (IST) for tovecimig (CTX-009), a bispecific antibody targeting DLL4 and VEGF-A, in patients with biliary tract cancer (BTC) [1][2] - The trial is being conducted at The University of Texas MD Anderson Cancer Center and aims to evaluate the efficacy and safety of tovecimig in combination with standard first-line treatments [1][2] - The company has also reported that tovecimig met the primary endpoint in a separate Phase 2/3 study, with results for secondary endpoints expected in Q4 2025 [2] Company Overview - Compass Therapeutics is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for oncology [4] - The company aims to target critical biological pathways involved in tumor growth and immune response, with a pipeline designed to address multiple human diseases [4] - Founded in 2014 and headquartered in Boston, Massachusetts, Compass Therapeutics is advancing its product candidates through clinical development [4] Product Information - Tovecimig is designed to block DLL4 and VEGF-A signaling pathways, which are essential for angiogenesis and tumor vascularization [3] - Preclinical and early clinical data suggest that tovecimig has shown robust anti-tumor activity across various solid tumors, including cholangiocarcinoma and pancreatic cancer [3] - The ongoing COMPANION-002 trial is evaluating tovecimig in combination with paclitaxel for previously treated advanced metastatic BTC [3] Trial Details - The IST will involve approximately 50 patients with unresectable or metastatic BTC, assessing safety and tolerability alongside a standard regimen of gemcitabine, cisplatin, and durvalumab [2] - The primary objectives include evaluating 6-month progression-free survival and determining the maximum tolerated dose of tovecimig [2] - Secondary objectives will assess overall response rate, duration of response, progression-free survival, and overall survival [2]
Compass Therapeutics Announces First Patient Dosed in an Investigator Sponsored Trial of Tovecimig in the First-Line Setting for Patients with Biliary Tract Cancer